Analyst Price Target is $12.00
▲ +1,100.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for NeuBase Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,100.00% upside from the last price of $1.00.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in NeuBase Therapeutics. This Buy consensus rating has held steady for over two years.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.